Zeit Medical Seed

Primary contact

Zeit Medical has developed a brain-monitoring wearable device that could identify the signs of an impending stroke from the EEG monitoring of brainwaves. This way, it could help raise the alarm and get people to the hospital fast enough to mitigate the stroke's damage and potentially save lives. The company's "breakthrough AI and cutting edge bioelectronics" provide peace of mind to those affected by neurological injury and empower physicians to diagnose and treat with precision. Zeit Medical envisions its device and technology being used both in the hospital and at home. The company is part of Y Combinator's Summer 2021 cohort.
Primary contact

Funding πŸ’°

Last round πŸ”— $2M
October 29, 2021.
Select investors SeedToB Capital, DigiLife, Y Combinator, Gaingels, Northsouth Ventures, Tamar Capital, Axial, Citta Capital

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Zeit Medical can make a big impace as 10 million Americans live with a risk of stroke, less than 10% of stroke victims in the US receive treatment, and 1 in 10 of all ischemic stroke victims die each year. πŸ”—
  • The company's technology could significantly lower the risk and cost of at-home and disability care for many people who might otherwise have to regularly visit the hospital.
  • Zeit Medical is working on a full FDA clearance and has so far received "Breakthrough designation," but it may still be a year or two before it's widely available. That is still a short lead time for a medical device, and investors thought this was an opportunity for both impact and ROI. πŸ”—
  • Orestis Vardoulis, Zeit's co-founder & CEO, has authored 20+ publications in prestigious journals and has filed for a variety of patents at the intersection of materials technology and medical devices. Most recently Orestis was a Stanford Biodesign Innovation Fellow and since the founding of Zeit Medical he has been focusing on his CEO role and Zeit's RnD.
  • Urs Naber, also a Zeit Medical co-founder, has contributed to several pediatric medical devices development projects, prior to joining the Stanford Biodesign Fellowship program. He has also spent time in Shanghai and Beijing working with a med-tech focused private equity company and closely follows the regulatory developments in Europe and Asia.
Last update: November 28, 2021